“…Perceptible adverse events would leave patients and consumers with negative impressions of products, and the pharmaceutical and cosmetic industries have struggled to predict and/or avoid phototoxic events. In the early 2000s, regulatory agencies, including the Food and Drug Administration, the European Medicines Agency, and the Organization for Economic Cooperation and Development (OECD), established guidance on photosafety testing of medicinal products (EMEA/CPMP, 2002, 2008FDA/CDER, 2002;OECD, 2004). In 2014, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) established the ICH S10 guideline (ICH, 2014), and this guidance describes photosafety assessment strategies on the basis of photochemical/photobiological properties and in vivo pharmacokinetic (PK) behaviors in UV-exposed tissues, such as skin and eyes.…”